Caris Life Sciences (CAI) Capital Expenditures (2024 - 2026)

Caris Life Sciences' Capital Expenditures history runs 3 years deep, the most recent figure standing at -$153000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 325.0% year-over-year to -$153000.0; the TTM figure through Mar 2026 stood at -$165000.0 (changed N/A YoY), while the FY2025 annual figure was -$48000.0, down 100.57% from the prior year.
• Capital Expenditures for Q1 2026 stood at -$153000.0, up from -$11.2 million in the prior quarter.
• The five-year high for Capital Expenditures was $8.3 million in Q4 2024, with the low at -$11.2 million in Q4 2025.
• The 3-year median for Capital Expenditures is -$36000.0 (2025), against an average of $559571.4.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures soared 270.23% in 2025, then slumped 325.0% in 2026.
• Caris Life Sciences' Capital Expenditures stood at $8.3 million in 2024, then sank by 235.38% to -$11.2 million in 2025, then jumped by 98.64% to -$153000.0 in 2026.
• Business Quant data shows CAI's Capital Expenditures at -$153000.0 in Q1 2026, -$11.2 million in Q4 2025, and $7.1 million in Q3 2025.